Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 09, 2016 5:07 AM ET

Healthcare Equipment and Supplies

Company Overview of Singulex, Inc.

Company Overview

Singulex, Inc. develops and manufactures immunodiagnostic products. It provides immunoassay systems, which includes benchtop analytical instrumentation, integrated and prepared reagents for ultrasensitive immunoassays, and software to automatically analyze data and display detailed assay reports. The company also offers molecule counting products; ultrasensitive immunoassays, such as inflammation, cardiovascular, neurology, oncology, metabolism, and toxicity; SgxHD for cardiovascular monitoring; and custom services and support, such as sample testing, assay development, and antibody derivatization. Singulex, Inc. was formerly known as BioProfile Corporation and changed its name to Singulex, ...

1650 Harbor Bay Parkway

Suite 200

Alameda, CA 94502

United States

Founded in 1997

177 Employees





Key Executives for Singulex, Inc.

Chief Executive Officer, President and Director
Age: 50
Chief Financial Officer and Principal Accounting Officer
Age: 46
Chief Commercial Officer and Senior Vice President of Sales & Marketing
Age: 63
Vice President of Business Development
Compensation as of Fiscal Year 2015.

Singulex, Inc. Key Developments

Singulex, Inc. Presents at JPMorgan 34th Annual Healthcare Conference, Jan-14-2016 10:00 AM

Singulex, Inc. Presents at JPMorgan 34th Annual Healthcare Conference, Jan-14-2016 10:00 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, California, United States. Speakers: Guido Baechler, Chief Executive Officer, President and Director.

Singulex Demonstrates Ultrasensitive "Sgx Clarity(TM) System" at AACC 2015

Singulex, Inc. announced that it will demonstrate the "Sgx Clarity System" in the company booth at the 2015 American Association for Clinical Chemistry (AACC) Annual Meeting from July 26 to 30, 2015 (booth number #2758). Utilizing Singulex's proprietary second generation SMC technology, the fully-automated Sgx Clarity System is designed to detect low abundance biomarkers at levels down to femtograms/mL. The Sgx Clarity System is on track for full commercialization in Europe in 2016. In addition, the company highlighted multiple scientific presentations that will take place at the AACC meeting that demonstrate the ultrasensitive protein detection of SMC technology using prototypes of the Sgx Clarity System (the Sgx Clarity System is in development; not available for commercial sale). Importantly, the abstract entitled High-sensitivity cardiac troponin I in a large community-based population at risk for cardiovascular disease won a National Academy of Clinical Biochemistry (NACB) Distinguished Abstract Award. Each year, the NACB, the professional arm of the American Association for Clinical Chemistry, acknowledges several posters to be presented with an NACB distinction. In Dr. Alan Wu's poster, research that evaluated ultrasensitive cardiac troponin I (hs-cTnI) levels from 23,000 patients' blood samples, processed and analyzed using Singulex's SMC technology, highlights the impact of comorbidities on heart disease. The research concluded that differences in hs-cTnI levels exist between age and gender which may represent subclinical disease. Moreover, it may be possible to establish hs-cTnI concentrations for subgroups of patients that may more accurately define patients at risk for cardiovascular disease.

Merck Millipore Enters into Agreement to Acquire Exclusive Rights to Singulex's Ultra-Sensitive Single Molecule Counting Technology

Merck Millipore and Singulex announced that they have entered into a definitive agreement under which Merck Millipore will control and manage the Singulex Life Science Research business. Under the terms of the agreement, Merck Millipore will pay Singulex an upfront payment, royalties and additional payments based upon achievement of certain commercial milestones. Merck Millipore will have exclusive rights to further develop and commercialize the SMC technology for research applications worldwide. Reliable, ultra-sensitive protein detection is a critical unmet need in life science research. Current technologies allow detection of only approximately 5% of proteins in the entire proteome due to the very low abundance of many biomarkers, leaving the vast majority of proteins virtually undetectable. The SMC technology is a novel, patented technology combining signal enhancement and background reduction coupled with low volume sampling to achieve ultra-high sensitivity protein detection. The clinical benefits of this technology have been well-established and Singulex will continue to operate a large and successful clinical service business based on novel, enabling SMC assays. Financial and other terms of the deal were not disclosed.

Similar Private Companies By Industry

Company Name Region
Medco Supply Company, Inc. United States
Photo Therapeutics, Inc. United States
Nexgen Spine Inc. United States
Integrated Diagnostics Inc. United States
Vicon Fiber Optics Corp. United States

Recent Private Companies Transactions

May 21, 2015
Singulex, Inc., Singulex Life Science Research Business

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Singulex, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at